Mitral valvuloplasty, a better alternative *1Comparative study between valve reconstruction and replacement for rheumatic mitral valve disease

Valvuloplasty is now a well accepted alternative method of surgical treatment of mitral valve disease. To analyse its relative performance in rheumatic valvulopathies, three groups of patients who had mitral valvuloplasty (1980-1984; 241 patients) or mitral valve replacement with mechanical (1980-1984; 386 patients) or biological prostheses (1976-1980; 289 patients) were reviewed. The early mortality was 3.3% for valvuloplasty, 7.8% for mechanical valve replacement and 6.6% for bioprostheses (P less than 0.05). Late mortality occurred at the rate of 2.6% per patient year (15 patients) for valvuloplasty, 5.7% per patient year (70 patients) for mechanical valves and 7.4% per patient year (41 patients) for bioprostheses (P less than 0.01), but valve-related mortality was 1.0% per patient year, 2.5% per patient year and 4.2% per patient year, respectively (P less than 0.01). Reoperation was more frequent after valve replacement with bioprostheses (6.7% per patient year) than after valvuloplasty (4.3% per patient year) and after mechanical valve replacement (1.5% per patient year; P less than 0.02), and was necessitated mainly by residual or recurrent valve dysfunction after valvuloplasty, bland or infected periprosthetic leaks in mechanical valves and degradation of bioprostheses. Valve failure occurred at the rate of 6.1% per patient year for valvuloplasty, 5.7% per patient year for mechanical valves and 11.1% per patient year for bioprostheses (P less than 0.05). In actuarial terms, global survival and survival free from valve related complications were 90% +/- 4% and 70% +/- 6% for patients who had valvuloplasty, 76% +/- 3% and 71% +/- 5% for the mechanical prosthetic replacement group and 62% +/- 7% and 30% +/- 7% for bioprosthetic valve replacement.(ABSTRACT TRUNCATED AT 250 WORDS)